Physician profile
Nermi Onat
NPI 1407869985
$1,864.81
in general payments reported to CMS, 2019-2025
21 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $337 · 2023: $366 · 2024: $346 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.33 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $314.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $220.18 | 2021-2025 | Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.75 | 2021-2023 | Trulance, Xifaxan |
| Currax Pharmaceuticals LLC | $99.63 | 2021-2025 | Contrave, Onzetra Xsail |
| Lilly USA, LLC | $55.85 | 2024-2025 | Zepbound, Mounjaro |
| Ibsa Pharma INC. | $54.68 | 2021-2025 | Tirosint, Licart, Flector |
| Acella Pharmaceuticals, LLC | $50.28 | 2024-2025 | NP Thyroid 60 |
| Cumberland Pharmaceuticals, INC. | $43.45 | 2023-2025 | Kristalose |
| Cleerly, INC. | $41.09 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Arbor Pharmaceuticals, INC. | $40.94 | 2021 | |
| Phadia US INC. | $36.34 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $33.48 | 2024 | Nuzyra |
| Renalytix Ai, INC. | $31.83 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Abbott Laboratories | $24.04 | 2025 | Freestyle Libre 3 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.52 | 2022 | |
| Seqirus USA INC | $19.00 | 2025 | Flucelvax, Fluad |
| Merck Sharp & Dohme LLC | $17.91 | 2025 | Lagevrio |
| Daiichi Sankyo INC. | $16.28 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $16.13 | 2023 | Hyqvia |
| Abbvie INC. | $14.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nermi Onat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.